← Leaderboards
Xiaodong Wang
Univ Of North Carolina Chapel Hill
$2,479,253
Attributed
$5,301,267
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,301,267 · 3
By mechanism
R01$5,301,267 · 3
Top collaborators
- Douglas K Graham10 shared
- Anutosh Chakraborty2 shared
- Dmitri Kireev2 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Anutosh Chakraborty$4,228,389
- Charles M Perou$46,508,459
- Dmitri Kireev$921,810
- Chad V Pecot$5,843,920
- Aaron C Anselmo$3,695,735
Others in their field
Other Emerging Leaders on “Property”
- Valerie Koch · University Corporation For Atmospheric Res$247,762,266
- Susan Abushakra · Alzheon, Inc.$47,265,244
- John Hobbs · Suny At Stony Brook$42,194,917
- Christopher Bee · Suny At Stony Brook$41,239,084
- John Damon Chodera · Sloan-Kettering Inst Can Research$39,689,447
- Eric C Palm · Florida State University$35,115,872
Research focus
PropertyIn VivoPhosphotransferasesTargeted AgentCellular AssayLeadMacrophagePharmaceutical PreparationsQuality Of LifeCellsClinical ApplicationFamilyPharmaceutical ChemistryBiochemicalCancer ModelFamily MemberImmuneCancer CellImmunocompetentDiagnosisCell PhysiologyEffective TherapyCell SurvivalAdvanced Malignant Neoplasm
Grant awards (12)
Novel IP6K1 inhibitors for treatment of NAFLD/NASH$569,142
R01 · FY2025 · DK · contact PI
Novel TYRO3 inhibitors for treatment of cancer$323,080
R01 · FY2025 · CA · contact PI
Novel IP6K1 inhibitors for treatment of NAFLD/NASH$646,254
R01 · FY2024 · DK · contact PI
MERTK/AXL dual inhibitors provide novel treatment for cancer by targeting tumor cells and activating anti-tumor immunity$463,267
R01 · FY2024 · CA · contact PI
Novel TYRO3 inhibitors for treatment of cancer$306,926
R01 · FY2024 · CA · contact PI
MERTK/AXL dual inhibitors provide novel treatment for cancer by targeting tumor cells and activating anti-tumor immunity$497,060
R01 · FY2023 · CA · contact PI
Novel TYRO3 inhibitors for treatment of cancer$316,619
R01 · FY2023 · CA · contact PI
MERTK/AXL dual inhibitors provide novel treatment for cancer by targeting tumor cells and activating anti-tumor immunity$497,060
R01 · FY2022 · CA · contact PI
Novel TYRO3 inhibitors for treatment of cancer$316,619
R01 · FY2022 · CA · contact PI
MERTK/AXL dual inhibitors provide novel treatment for cancer by targeting tumor cells and activating anti-tumor immunity$507,204
R01 · FY2021 · CA · contact PI
Novel TYRO3 inhibitors for treatment of cancer$336,957
R01 · FY2021 · CA · contact PI
MERTK/AXL dual inhibitors provide novel treatment for cancer by targeting tumor cells and activating anti-tumor immunity$521,079
R01 · FY2020 · CA · contact PI